WELLBUTRIN FOR DEPRESSION IN DIABETIC PATIENTS

维布特林 (Wellbutrin) 治疗糖尿病患者抑郁症

• 批准号: 7377217
• 负责人: PATRICK J LUSTMAN
• 金额: $ 2.87万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377217
• 关键词: WELLBUTRIN; DEPRESSION; DIABETIC; PATIENTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetes is present in approximately 20,000,000 adults and is a leading cause of morbidity and mortality. Hyperglycemia is the principal cause of the neuropathic, micro- and macrovascular complications of diabetes; accordingly maintenance of normoglycemia has long been the focus of diabetes therapy. However, even with aggressive treatment, glycemic control sufficient to prevent the development of diabetes complications is rarely achieved (1,2). This has intensified the search for modifiable factors that could improve the course of diabetes, and depression management may be one of these factors. Clinical depression, present in approximately 25% of patients with diabetes (type 1 or type 2), is associated with hyperglycemia and with increased risk for complications, particularly macrovascular disease. These observations led to a series of clinical trials to determine whether these associations could me manipulated through depression treatment. These studies indicate that improvement in depression is associated with short-term improvement in glycemic control and insulin resistance; however, the effects of treatment on mood and glucose regulartion are not always parallel nor uniformly prodiabetic. If as happens the depression intervention induces weight gain, a seperate factor promoting hyperglycemia and insulin resistance, the overall effects of depression therapy in the face of diabetes would be devalued. As yet, and agent having concomitant positive and durable effects on depression, glycemic control, and weight is desirable but has not yet been identified.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。大约有 20,000,000 名成年人患有糖尿病，是发病和死亡的主要原因。高血糖是糖尿病神经病变、微血管和大血管并发症的主要原因。因此维持正常血糖一直是糖尿病治疗的重点。然而，即使采用积极治疗，也很少能实现足以预防糖尿病并发症发生的血糖控制 (1,2)。这加强了对可以改善糖尿病病程的可改变因素的寻找，而抑郁症管理可能是这些因素之一。大约 25% 的糖尿病（1 型或 2 型）患者存在临床抑郁症，它与高血糖有关，并且与并发症（尤其是大血管疾病）的风险增加有关。这些观察导致了一系列临床试验，以确定这些关联是否可以通过抑郁症治疗来操纵。这些研究表明，抑郁症的改善与血糖控制和胰岛素抵抗的短期改善有关。然而，治疗对情绪和血糖调节的影响并不总是平行或一致地促进糖尿病。如果抑郁干预会导致体重增加（这是促进高血糖和胰岛素抵抗的一个单独因素），那么抑郁治疗在糖尿病面前的整体效果就会大打折扣。迄今为止，对抑郁、血糖控制和体重具有伴随的积极和持久作用的药剂是令人期望的，但尚未被鉴定。